Crescent Biopharma (CBIO) Earnings Analysis

Crescent Biopharma (CBIO) next reports earnings on 2026-07-30, consensus EPS -0.7 USD. Last quarter (2026-04-29) it beat with EPS -0.7 USD vs -0.85 USD est (+17.6%). It has beaten estimates in 2/6 recent quarters (33%). Trailing P/E -1.45.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does CBIO next report earnings?

Next earnings date2026-07-30
Consensus EPS estimate-0.7 USD
Revenue estimate0.00B

CBIO earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-04-29-0.7 USD-0.85 USD+17.6%Beat
2026-02-26-4.01 USD-2.22 USD-80.6%Miss
2025-11-06-1.27 USD-1.01 USD-25.7%Miss
2025-07-31-4.93 USD-2.69 USD-83.3%Miss
2025-02-13-0.11 USD-0.16 USD+31.3%Beat
2024-11-13-0.15 USD-0.11 USD-36.4%Miss

Beat rate: 2/6 (33%) over reported quarters with consensus data.

CBIO valuation and analyst view

Trailing P/E-1.45
Trailing EPS-5.33185 USD
Price / book2.62
Dividend yield0.00%
Market cap0.43B
Analyst consensusBuy (8 buy / 5 hold / 0 sell)
Avg price target31.4 USD

Related research pages

Frequently asked questions

When is Crescent Biopharma (CBIO)'s next earnings date?

Crescent Biopharma is next scheduled to report on 2026-07-30, with a consensus EPS estimate of -0.7 USD and revenue estimate of 0.00B.

Did CBIO beat earnings last quarter?

In its 2026-04-29 report, CBIO posted EPS of -0.7 USD versus a -0.85 USD estimate — a beat of 17.6%.

What is CBIO's earnings track record?

Over the last 6 reported quarters with consensus data, CBIO beat estimates 2 times (33%).

What is CBIO's current P/E ratio and EPS?

CBIO trades at a trailing P/E of -1.45 on trailing EPS of -5.33185103727279 USD.

What do analysts rate CBIO?

Analyst consensus is "Buy" across 13 ratings (0 strong buy, 8 buy, 5 hold, 0 sell, 0 strong sell). Average 12-month price target: 31.4 USD.